

## Comment on Media Article Published in Australian Financial Review

**Sydney Australia, 8 September 2020:** Recce Pharmaceuticals (**ASX: RCE**) advises an online article in the Australian Financial Review today titled “**Biotech stars benefit from R&D rebate scheme**” states: “*the CSIRO and Doherty Institute...have chosen Recce’s compounds RECCE<sup>®</sup> 327 and RECCE<sup>®</sup> 529 as their priority-one test candidate against coronavirus...*”.

As detailed in the announcement released to the Australian Stock Exchange on 20 July 2020, Recce confirms that CSIRO and Doherty Institute are only testing RECCE<sup>®</sup> 327 as part of the SARS-CoV-2 Antiviral Screening Program. RECCE<sup>®</sup> 529 has not at this time been assessed or accepted by CSIRO or the Doherty Institute.

The fee-for-service SARS-CoV-2 Antiviral Screening Program is undertaken as a collaboration between CSIRO and the Doherty Institute. While Recce is delighted that one of its compounds has been accepted to the screening program, such acceptance is not an indication that the compound is safe or effective as a treatment of SARS-CoV-2.

Recce Pharmaceuticals confirms it is in compliance with its continuous disclosure obligations.

This announcement was authorised by the Recce Pharmaceuticals Chief Executive Officer.



**ASX:** RCE

**Head Office:** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (02) 8075 4585 **F** +61 (02) 8075 4584

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA